Patents Assigned to Cellectis
-
Publication number: 20250129377Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).Type: ApplicationFiled: June 18, 2024Publication date: April 24, 2025Applicant: CellectisInventors: Nicholas Baltes, Javier Gil Humanes
-
Publication number: 20240309397Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppresive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular, TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection. of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: December 6, 2023Publication date: September 19, 2024Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 12012607Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).Type: GrantFiled: May 2, 2019Date of Patent: June 18, 2024Assignee: CellectisInventors: Nicholas Baltes, Javier Gil Humanes
-
Patent number: 11959091Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.Type: GrantFiled: November 20, 2020Date of Patent: April 16, 2024Assignee: CellectisInventors: Philippe Duchateau, André Choulika, Laurent Poirot
-
Publication number: 20230357719Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSI or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.Type: ApplicationFiled: May 22, 2023Publication date: November 9, 2023Applicant: CellectisInventors: Philippe DUCHATEAU, Laurent POIROT
-
Patent number: 11624072Abstract: Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein.Type: GrantFiled: July 9, 2019Date of Patent: April 11, 2023Assignee: CellectisInventors: Wenzheng Zhang, Feng Zhang
-
Patent number: 11498971Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.Type: GrantFiled: May 8, 2019Date of Patent: November 15, 2022Assignee: CellectisInventor: Roman Galetto
-
Publication number: 20220348955Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: June 24, 2022Publication date: November 3, 2022Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20220177914Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: February 17, 2022Publication date: June 9, 2022Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11312972Abstract: Materials and methods are provided for making plants with altered levels of amino acids, particularly by making controlled frameshift mutations in genes that are highly expressed in plant leaves or plant seeds.Type: GrantFiled: November 16, 2017Date of Patent: April 26, 2022Assignee: CellectisInventors: Nicholas Baltes, Song Luo
-
Patent number: 11136566Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.Type: GrantFiled: January 2, 2019Date of Patent: October 5, 2021Assignee: CellectisInventors: Philippe Duchateau, Alexandre Juillerat, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva
-
Patent number: 11077144Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: November 16, 2020Date of Patent: August 3, 2021Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Patent number: 11072644Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.Type: GrantFiled: November 9, 2015Date of Patent: July 27, 2021Assignees: Allogene Therapeutics, Inc., CellectisInventors: Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
-
Publication number: 20210220405Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 11, 2021Publication date: July 22, 2021Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11014989Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.Type: GrantFiled: January 25, 2016Date of Patent: May 25, 2021Assignee: CellectisInventors: Julianne Smith, Julien Valton, Alexandre Juillerat, Philippe Duchateau, Barbra Johnson Sasu, Arvind Rajpal
-
Publication number: 20210147868Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.Type: ApplicationFiled: November 20, 2020Publication date: May 20, 2021Applicant: CellectisInventors: Philippe DUCHATEAU, André CHOULIKA, Laurent POIROT
-
Patent number: 11007224Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: November 16, 2020Date of Patent: May 18, 2021Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Publication number: 20200407682Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.Type: ApplicationFiled: July 27, 2020Publication date: December 31, 2020Applicant: CellectisInventors: Philippe DUCHATEAU, Laurent POIROT
-
Patent number: 10874693Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: May 12, 2014Date of Patent: December 29, 2020Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Patent number: 10815500Abstract: The present invention relates to Transcription Activator-Like Effector (TALE) derived proteins that allow efficient targeting and/or processing of double stranded nucleic acid sequences. The proteins of the invention are typically chimeric protein monomers composed of a core scaffold comprising Repeat Variable Dipeptide regions (RVDs) having binding specificity to a DNA target sequence, to which is fused a catalytic domain to its N-terminus. This later catalytic domain, which can be a monomer of a nuclease, is placed at this position to possibly interact with another catalytic domain fused to another TAL monomer, such that, when the monomers are binding to their respective target DNA sequences, both catalytic domains form a catalytic entity likely to process DNA in the proximity of these target sequences. This new TAL architecture makes it possible to target only one DNA strand, which is not the case, for instance, with classical TALEN architectures.Type: GrantFiled: June 5, 2013Date of Patent: October 27, 2020Assignee: CellectisInventors: Alexandre Juillerat, Philippe Duchateau